Systemic lupus erythematosus (SLE) patients tends to have a higher risk of developing lymphoid malignancies. The majority of such tumors are of a B cell origin. However, it is known that the T cell lymphoma subtypes in SLE patients are quite rare. Here, we describe a case of peripheral T cell lymphoma, unspecified (PTCL-U) that occurred in a 50-year-old female SLE patient. The lymphoma was located at the bilateral cervical and mediastinal lymph nodes. The staging workup revealed no evidence of any other organ involvement. Epstein-Barr virus messenger RNA was detected in the serum, but not in the lymph nodes. She received front-line chemotherapy with the CHOP regimen and she achieved complete remission. She then subsequently received high-dose chemotherapy with autologous peripheral stem cell transplantation. The patient currently remains in a clinical and serological state of remission for the SLE and PTCL until the time of this report 18 months after chemotherapy, and this was followed by autologous peripheral blood stem cell transplantation. 
INTRODUCTION
A recent International Lymphoma Study Group study of 1,378 cases of non-Hodgkin's lymphoma (NHL) has found that 7% of the cases represented peripheral T-cell lymphoma (PTCL). 1) PTCL is not geographically distributed evenly throughout the world. The condition develops more frequently in Asia than in Western countries. 2) There are many causes of the development of NHL and infection with viruses, such as Epstein-Barr virus (EBV) is one of them. 3, 4) Systemic lupus erythematosus (SLE) also results in a higher risk for the development of all cancer types. Hodgkin's lymphoma, Burkitt's lymphoma, low-grade lymphoma, and diffuse large B-cell lymphoma have been reported as SLE-associated neoplasms. 5) However, it is known that T-cell lymphoma subtypes are rare in SLE patients. Here, we present a case of PTCL that occurred two months after the onset of SLE.
CASE REPORT
A 50-year-old woman was referred to the Department of Medical Oncology from the Department of Rheumatology due to a palpable neck mass that had increased in size over one week. The patient had suffered from polyarthralgia over three years, and presented two months prior, complaining of high-grade fever, arthralgia, and skin rash. At that time, the patient was diag- 
DISCUSSION
Patients with autoimmune diseases, such as rheumatoid arthritis, SLE, Sjögren's syndrome, psoriasis, and celiac disease, are more susceptible to the development of lymphomas. 6) A recent, large pooled analysis demonstrated that SLE was associated with a 2.7-fold increased risk of NHL. In contrast, the T-cell NHL risk was greater for patients with celiac disease and psoriasis. 7) Mature B cell lymphomas are the predominant pathologic subtype in SLE patients, and diffuse large B cell lymphoma has been identified as the most frequent subtype.
5,7)
However, it has been demonstrated that T-cell lymphomas are quite rare in SLE patients. Moreover, the synchronous or metasynchronous occurrence of SLE with T-cell malignancy is rarely reported.
The reasons for the increased risk of NHL in patients with SLE remain largely unknown. Immune dysregulation, immunosuppressive drugs, and EBV infection may act as common etiologic factors in both disorders. 9, 10) Genetic abnormalities, including dysfunction in apoptosis and lymphocyte proliferation, may represent a common pathway that links SLE and lymphoproliferative malignancies. 
